Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso
NCT ID: NCT03269279
Last Updated: 2019-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
100 participants
INTERVENTIONAL
2017-05-20
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days Gestation
NCT01966874
Misoprostol for the Treatment of Incomplete Abortion
NCT00670761
Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan
NCT02235155
Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Ukraine
NCT02415894
Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh
NCT01798017
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Medical abortion arm
200mg of Mifepristone and repeat doses of 400mcg of misoprostol every 3 hours administered for medical abortion in 2nd trimester
Mifepristone
Medication used in conjunction with misoprostol for abortion
Misoprostol
Medication used in conjunction with mifepristone for abortion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mifepristone
Medication used in conjunction with misoprostol for abortion
Misoprostol
Medication used in conjunction with mifepristone for abortion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be willing to undergo surgical completion if necessary
* Have no contraindications to study procedures, according to provider
* Be willing and able to consent to participate in the study
* Be willing to follow study procedures
* Respect legal indications for obtaining an abortion
Exclusion Criteria
* Any contraindications to vaginal delivery, including placenta previa
* Previous transmural uterine incsion
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gynuity Health Projects
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Blandine Thieba, MD
Role: STUDY_DIRECTOR
SOGOB
Evelyne Komboigo, MD
Role: STUDY_CHAIR
SOGOB
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHUSS
Bobo-Dioulasso, , Burkina Faso
CMA Boromo
Boromo, , Burkina Faso
CHUYO
Ouagadougou, , Burkina Faso
CHR Ouahigouya
Ouahigouya, , Burkina Faso
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Evelyne Komboigo, MD
Role: primary
Evelyne Komboigo, MD
Role: primary
Evelyne Komboigo, MD
Role: primary
Evelyne Komboigo, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1036
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.